Is BioAge Labs, Inc. (BIOA) a Top Longevity Biotech Stock to Watch After New Analyst Coverage?
TheFly reported on May 13 that BIOA received newly initiated coverage with a Buy rating and a $40 price target by BITG.
Bioage Labs Inc. (BIOA)
Market is closed
Sector: Pharmaceutical Preparations
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.00 | 3,000 | $54,000.00 | 3,000 | 2024-09-27 | Filing | |
| $18.00 | 2,632 | $47,376.00 | 2,632 | 2024-09-27 | Filing | |
| $19.90 | 25,306 | $503,589.40 | 1,119,195 | 2024-10-03 | Filing | |
| $19.73 | 67,096 | $1,323,804.08 | 1,093,889 | 2024-10-02 | Filing | |
| $19.73 | 126,793 | $2,501,625.89 | 1,026,793 | 2024-10-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.81 | 8,820 | $157,084.20 | 0 | 2026-04-01 | Filing | |
| $20.30 | 7,433 | $150,889.90 | 0 | 2026-03-02 | Filing | |
| $18.75 | 7,433 | $139,368.75 | 0 | 2026-02-02 | Filing | |
| $21.08 | 1,923 | $40,538.38 | 22,408 | 2026-01-13 | Filing | |
| $20.54 | 11,663 | $239,548.69 | 24,331 | 2026-01-13 | Filing |
News See All
8 Best Small Cap Pharma Stocks to Buy Right Now
Despite the concerns surrounding the Iran War, Haig Bathgate, CEO of Callanish Capital, stated on CNBC on May 7 that he was optimistic about global stocks.
7 Best Small-Cap Drug Manufacturing Stocks to Buy According to Hedge Funds
In this article, we will take a look at some of the small-cap drug manufacturing stocks that are highly favored by hedge funds.
11 Best New Penny Stocks to Buy Right Now
On July 28, the Opening Bid team at Yahoo Finance and Victoria Fernandez, chief market strategist at Crossmark Global Investments, discussed the rise in cheap stock trading and what it can mean for the...
BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025
BioAge Labs, Inc. (NASDAQ:BIOA), a clinical-stage biotech innovator, announced today the completion of IND-enabling studies for its groundbreaking oral NLRP3 inhibitor, BGE-102, targeting obesity.
BioAge Labs, Inc. (BIOA): A Bull Case Theory
We came across a bullish thesis on BioAge Labs, Inc. (BIOA) on Substack by Ragnarok Research. In this article, we will summarize the bulls’ thesis on BIOA. BioAge Labs, Inc.
BioAge Labs, Inc. (BIOA): A Bull Case Theory
We came across a bullish thesis on BioAge Labs, Inc. (NASDAQ:BIOA) on Value Investing Subreddit Page by value1024. In this article, we will summarize the bulls’ thesis on BIOA. BioAge Labs, Inc.
10 Best All-Time Low Stocks To Buy Right Now
With November coming to a close, while markets are focused on the future of artificial intelligence and the degree of profitability that AI firms can extract from their multi-billion dollar investments...
13G Filing: Sabby Capital and Bioamber Inc. (BIOA)
Bioamber Inc. (NYSE:BIOA): Hal Mintz's Sabby Capital filed an amended 13D.
You can check out Sabby Capital's latest holdings and filings here.
Bioamber Inc (BIOA): How It Stacks Up Against Its Peers
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity.
Hedge Fund Resource Center